Centaurus Financial, Inc. Sorrento Therapeutics, Inc. Transaction History

Centaurus Financial, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	BUY	$2.0 - $4.9 $5,400 - $13,230	2,700 Added 7.19%	40,255 $94,000
Q4 2021 Feb 01, 2022	BUY	$4.65 - $7.23 $37,293 - $57,984	8,020 Added 27.15%	37,555 $175,000
Q3 2021 Nov 12, 2021	BUY	$7.41 - $10.99 $30,381 - $45,059	4,100 Added 16.12%	29,535 $225,000
Q3 2020 Nov 12, 2020	SELL	$6.17 - $18.82 $17,522 - $53,448	-2,840 Reduced 10.04%	25,435 $284,000
Q2 2020 Aug 13, 2020	BUY	$1.73 - $6.76 $475 - $1,859	275 Added 0.98%	28,275 $178,000
Q1 2020 Apr 21, 2020	BUY	$1.57 - $4.76 $7,850 - $23,800	5,000 Added 21.74%	28,000 $52,000
Q4 2019 Feb 12, 2020	BUY	$1.45 - $4.17 $7,250 - $20,850	5,000 Added 27.78%	23,000 $78,000
Q2 2019 Aug 15, 2019	BUY	$2.67 - $4.38 $47,830 - $78,463	17,914 Added 20830.23%	18,000 $48,000
Q1 2019 Jul 01, 2019	SELL	$1.86 - $5.94 $33,320 - $106,409	-17,914 Reduced 99.52%	86 $18 Million
Q1 2019 May 13, 2019	BUY	$1.86 - $5.94 $33,480 - $106,920	18,000 New	18,000 $86,000
Q3 2018 Nov 05, 2018	SELL	$4.22 - $7.5 $12,660 - $22,500	-3,000 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$4.75 - $8.0 $14,250 - $24,000	3,000 New	3,000 $22,000

5.47M

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

Get notified when there are updates to the investment portfolio of Centaurus Financial, Inc., based on Form 13F filings with the SEC.

Stay updated on Centaurus Financial, Inc. with notifications on news.